Royalty Pharma (RPRX) Revenue (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Revenue data on file, last reported at $630.6 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 10.97% year-over-year to $630.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 billion (up 7.8% YoY), and the FY2025 full-year result was $2.4 billion, up 5.06% from the prior year.
• Revenue rose to $630.6 million in Q1 2026, from $622.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $684.0 million in Q1 2023 to a low of $536.0 million in Q2 2022.
• A 5-year average of $580.2 million and a median of $568.2 million in 2025 frame the typical range for Revenue.
• Across the five-year window, Revenue grew 21.69% in 2023 and dropped 16.96% in 2024, its largest moves.
• Tracing RPRX's Revenue over 5 years: stood at $565.7 million in 2022, then grew by 5.36% to $596.1 million in 2023, then dropped by 0.41% to $593.6 million in 2024, then advanced by 4.78% to $622.0 million in 2025, then climbed by 1.38% to $630.6 million in 2026.
• Business Quant data shows RPRX's Revenue at $630.6 million in Q1 2026, $622.0 million in Q4 2025, and $609.3 million in Q3 2025.